MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on February 16, 2005; DOI: 10.1124/mol.104.010710


0026-895X/05/6705-1714-1722$20.00
Mol Pharmacol 67:1714-1722, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.010710v1
67/5/1714    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fagart, J.
Right arrow Articles by Rafestin-Oblin, M.-E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fagart, J.
Right arrow Articles by Rafestin-Oblin, M.-E.
ORIGINAL ARTICLE

The Met852 Residue Is a Key Organizer of the Ligand-Binding Cavity of the Human Mineralocorticoid Receptor

Jérôme Fagart, Cendrine Seguin, Grégory Maurice Pinon, and Marie-Edith Rafestin-Oblin

Institut National de la Santé et de la Recherche Médicale U478, Institut Fédératif de Recherche 02, Faculté de Médecine Xavier Bichat, Paris, France

Abstract

Spirolactones harboring various C7 substituents are aldosterone antagonists, and some of them are used in the treatment of essential hypertension. They bind to the human mineralocorticoid receptor and render it transcriptionally inactive. Structural analysis using a three-dimensional homology model of the ligand-binding domain of the receptor has revealed that the Met852 residue of the ligand-binding cavity faces the C7 substituent of spirolactones. We therefore tested the binding capacities of C7-substituted spirolactones in an in vitro system expressing either the mutant receptor, in which Met852 was replaced by alanine, or the wild-type receptor. The M852A mutation had almost no effect on the binding of C7-substituted spirolactones to mineralocorticoid receptor but dramatically reduced the capacity of the receptor to bind steroids with no C7 substituent (aldosterone, cortisol, deoxycorticosterone, and canrenone). cis-trans Cotransfection assays revealed that two spirolactones characterized by having a propyl group [7{alpha}-propyl-17{alpha}-hydroxy-3-oxo-preg-4-ene-21-carboxylic acid {gamma}-lactone (RU26752)] or a thioacetyl group (spironolactone) at the C7 position acquired agonist properties when bound to the mutant receptor. In contrast, mexrenone and eplerenone, both of which harbor an acetyl group at the C7 position, retained antagonist properties when bound to the mutant receptor. Overall, these findings indicate that Met852 acts as an organizer residue that plays two major roles: 1) it allows steroids with no substituent at the C7 position to be accommodated within the ligand-binding cavity; and 2) it is involved in the steric hindrance that prevents C7-substituted spirolactones from folding the receptor in its active state.


Received December 22, 2004; accepted February 16, 2005

Address correspondence to: Dr. M. E. Rafestin-Oblin, Institut National de la Santé et de la Recherche Médicale U478, Faculté de Médecine Xavier Bichat; 16, rue Henri Huchard, 75870 Paris Cedex 18, France. E-mail: oblin{at}bichat.inserm.fr




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
J. Huyet, G. M. Pinon, M. R. Fay, J. Fagart, and M.-E. Rafestin-Oblin
Structural Basis of Spirolactone Recognition by the Mineralocorticoid Receptor
Mol. Pharmacol., September 1, 2007; 72(3): 563 - 571.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics